DuPont Nutrition & Health's regulatory team, from direct participation on joint IPEC and FDA working groups, has the expertise to assist its customers with understanding the FDA requirements for...
Dipankar Kaul -Head GMP Audits, Asia-Pacific- Novartis Technical Operations, envisages the many ways in which AI can transform pharma manufacturing operations and the present perspective of the science of...
Despite the disappointing history of drug development in pancreatic cancer, the current therapeutic pipeline and clinical development is headed in a promising direction, according to GlobalData, a leading data...
India is a Top 5 market, life sciences is fastest growing segment of GE Healthcare By Viveka Roychowdhury
Mohan G Joshi, International Business Coach and Former President, SCHOTT Glass India, expounds on how prospecting has changed and its importance in the current times
Pharmaceutical manufacturers must act now to avoid production scheduling clashes as well as technical and cost challenges ahead of next year’s FMD deadlines
The advantage of EU FMD implementation may result in better traceability and avoid spurious or non registered drugs
Existence of Falsified Medicines over the pharmacy counter thus has remained a grave concern for regulators all over the world
Marketing Authorisation Holders (MAHs) will be required to upload their products serialisation codes to the European Medicines Verification Organisation (EMVO) hub
In less than four months, by February 9, 2019 the Falsified Medicines Directive (FMD) will be implemented in more than 30 countries in the European Economic Area
Rajdutt Shekhar Singh, Partner, Singh & Associates, shares insights on ways to effective marketing strategy
Sanjay Sharma, Head-Lifesciences, NCF, UK; Ritu Hasija, Director Corporate and Girish Arora, Managing Director, Alniche Lifesciences, India elaborate on strategies to handle and execute pharma licensing effectively
During a recent plant visit to Lupin’s Nagpur facility, Swati Rana in an interaction with Rajiv Desai, Executive VP - Corporate Quality, Lupin and Alok Ghosh, President - Technical...
Introduction of new drugs in the form of biosimilars will bring in new drug delivery system. The Indian pharma companies are focusing and investing considerable amount on research and...
Looking at the pipeline of biosimilars, India shall remain a major market for biosimilars. Dr Siddharth Dutta, Associate Vice President, Markets and Markets Research, gives a different outlook of...
In the third of a series of six articles, Organisation of Pharmaceutical Producers of India (OPPI) launches the Know Your Pill initiative, to educate patients on the untold story...
Dr Milind Antani, Anay Shukla and Darren Punnen from Nishith Desai Associates, give an insight on the scope of laws that regulate direct to patient advertising in India
Mohan G Joshi, International Business Coach and Former President, SCHOTT Glass India elaborates on unlocking the hitherto untapped potential of a business with customer voice
Leading manufacturers are enhancing their business operations and encouraging R&D activities
Jalpa Sonchhatra, Director, Financial Accounting Advisory Services, EY India speaks on the strategies needed to ensure compliance with IndAS 115
Faced with delays at ports and possible product recalls, industry hopes the DGFT will fix the issues with the DAVA portal as well as issue clarifications.But with just three...
The GlobalData report found that big pharma companies lag behind small bio-techs in R&D efforts
Sarthak Sarin (Principal Associate) and Bharat Gupta (Associate), Khaitan & Co, give an insight on the need for better regulations for governing e-pharmacies
GlobalData identified 819 clinical trials that have been initiated in the last 10 years (2008-17) to investigate I/O drug candidates
Is a pill, just a pill? Most definitely not
Pharma companies these days have to comply with a number of standards as governed by Good Manufacturing Practice (GMP) and FDA regulations as well as social audits
Rajdutt Shekhar Singh, Partner, Singh & Associates, gives an insight on the status and objective of pharmacovigilance programme in India